Treatment of vascular dementia and vascular cognitive impairment

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

OBJECTIVE: In patients with vascular dementia and vascular cognitive impairment, are acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and N-methyl-d-aspartate (NMDA) receptor antagonists (memantine) effective in improving cognitive function over placebo? METHODS: The question was addressed with a structured, evidence-based, clinical, neurologic practice review. Participants included consultant and resident neurologists, clinical epidemiologists, medical librarians, and clinical content experts. A critically appraised topic format was employed, with a clinical scenario, structured question, search strategy, appraisal, results, summary of evidence, commentary, and bottom-line conclusions. RESULTS: Eight relevant systematic reviews and randomized controlled trials were identified and served as the principal sources of information. The best evidence to date revealed that donepezil 5 mg/d [number needed to treat (NNT) = 10] was the most effective and best tolerated [number needed to harm (NNH) = 50] of the available agents. Galantamine 24 mg/d (NNT = 7) was also effective but less well tolerated (NNH = 7). Due to insufficient evidence, rivastigmine could not yet be recommended for the treatment of vascular dementia. Memantine appeared to be safe and well tolerated but did not demonstrate effectiveness across all cognitive outcomes and clinical global measures. CONCLUSION: Acetylcholinesterase inhibitors and NMDA receptor antagonists, in general, displayed promise as treatments for patients with vascular dementia and vascular cognitive impairment. The most effective, evidence-based treatments were donepezil and galantamine.

Original languageEnglish (US)
Pages (from-to)37-41
Number of pages5
JournalNeurologist
Volume13
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Rivastigmine
Galantamine
Vascular Dementia
Memantine
Blood Vessels
Numbers Needed To Treat
Cholinesterase Inhibitors
Librarians
Consultants
Cognition
Nervous System
Therapeutics
Randomized Controlled Trials
Placebos
donepezil
Cognitive Dysfunction
aspartic acid receptor

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment of vascular dementia and vascular cognitive impairment. / Demaerschalk, Bart M; Wingerchuk, Dean Marko.

In: Neurologist, Vol. 13, No. 1, 01.2007, p. 37-41.

Research output: Contribution to journalArticle

@article{a43e6133e3a94e418bf705d5a5a34275,
title = "Treatment of vascular dementia and vascular cognitive impairment",
abstract = "OBJECTIVE: In patients with vascular dementia and vascular cognitive impairment, are acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and N-methyl-d-aspartate (NMDA) receptor antagonists (memantine) effective in improving cognitive function over placebo? METHODS: The question was addressed with a structured, evidence-based, clinical, neurologic practice review. Participants included consultant and resident neurologists, clinical epidemiologists, medical librarians, and clinical content experts. A critically appraised topic format was employed, with a clinical scenario, structured question, search strategy, appraisal, results, summary of evidence, commentary, and bottom-line conclusions. RESULTS: Eight relevant systematic reviews and randomized controlled trials were identified and served as the principal sources of information. The best evidence to date revealed that donepezil 5 mg/d [number needed to treat (NNT) = 10] was the most effective and best tolerated [number needed to harm (NNH) = 50] of the available agents. Galantamine 24 mg/d (NNT = 7) was also effective but less well tolerated (NNH = 7). Due to insufficient evidence, rivastigmine could not yet be recommended for the treatment of vascular dementia. Memantine appeared to be safe and well tolerated but did not demonstrate effectiveness across all cognitive outcomes and clinical global measures. CONCLUSION: Acetylcholinesterase inhibitors and NMDA receptor antagonists, in general, displayed promise as treatments for patients with vascular dementia and vascular cognitive impairment. The most effective, evidence-based treatments were donepezil and galantamine.",
author = "Demaerschalk, {Bart M} and Wingerchuk, {Dean Marko}",
year = "2007",
month = "1",
doi = "10.1097/01.nrl.0000252919.46622.28",
language = "English (US)",
volume = "13",
pages = "37--41",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Treatment of vascular dementia and vascular cognitive impairment

AU - Demaerschalk, Bart M

AU - Wingerchuk, Dean Marko

PY - 2007/1

Y1 - 2007/1

N2 - OBJECTIVE: In patients with vascular dementia and vascular cognitive impairment, are acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and N-methyl-d-aspartate (NMDA) receptor antagonists (memantine) effective in improving cognitive function over placebo? METHODS: The question was addressed with a structured, evidence-based, clinical, neurologic practice review. Participants included consultant and resident neurologists, clinical epidemiologists, medical librarians, and clinical content experts. A critically appraised topic format was employed, with a clinical scenario, structured question, search strategy, appraisal, results, summary of evidence, commentary, and bottom-line conclusions. RESULTS: Eight relevant systematic reviews and randomized controlled trials were identified and served as the principal sources of information. The best evidence to date revealed that donepezil 5 mg/d [number needed to treat (NNT) = 10] was the most effective and best tolerated [number needed to harm (NNH) = 50] of the available agents. Galantamine 24 mg/d (NNT = 7) was also effective but less well tolerated (NNH = 7). Due to insufficient evidence, rivastigmine could not yet be recommended for the treatment of vascular dementia. Memantine appeared to be safe and well tolerated but did not demonstrate effectiveness across all cognitive outcomes and clinical global measures. CONCLUSION: Acetylcholinesterase inhibitors and NMDA receptor antagonists, in general, displayed promise as treatments for patients with vascular dementia and vascular cognitive impairment. The most effective, evidence-based treatments were donepezil and galantamine.

AB - OBJECTIVE: In patients with vascular dementia and vascular cognitive impairment, are acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and N-methyl-d-aspartate (NMDA) receptor antagonists (memantine) effective in improving cognitive function over placebo? METHODS: The question was addressed with a structured, evidence-based, clinical, neurologic practice review. Participants included consultant and resident neurologists, clinical epidemiologists, medical librarians, and clinical content experts. A critically appraised topic format was employed, with a clinical scenario, structured question, search strategy, appraisal, results, summary of evidence, commentary, and bottom-line conclusions. RESULTS: Eight relevant systematic reviews and randomized controlled trials were identified and served as the principal sources of information. The best evidence to date revealed that donepezil 5 mg/d [number needed to treat (NNT) = 10] was the most effective and best tolerated [number needed to harm (NNH) = 50] of the available agents. Galantamine 24 mg/d (NNT = 7) was also effective but less well tolerated (NNH = 7). Due to insufficient evidence, rivastigmine could not yet be recommended for the treatment of vascular dementia. Memantine appeared to be safe and well tolerated but did not demonstrate effectiveness across all cognitive outcomes and clinical global measures. CONCLUSION: Acetylcholinesterase inhibitors and NMDA receptor antagonists, in general, displayed promise as treatments for patients with vascular dementia and vascular cognitive impairment. The most effective, evidence-based treatments were donepezil and galantamine.

UR - http://www.scopus.com/inward/record.url?scp=33846264900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846264900&partnerID=8YFLogxK

U2 - 10.1097/01.nrl.0000252919.46622.28

DO - 10.1097/01.nrl.0000252919.46622.28

M3 - Article

C2 - 17215726

AN - SCOPUS:33846264900

VL - 13

SP - 37

EP - 41

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 1

ER -